{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T14:48:22Z","timestamp":1780930102770,"version":"3.54.1"},"reference-count":66,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T00:00:00Z","timestamp":1757462400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Nemonoxacin is a novel non-fluorinated quinolone antibacterial agent, characterized by a broad antibacterial spectrum, strong antibacterial activity, low protein binding rate, high oral bioavailability, and extensive tissue distribution. Its unique pharmacological properties confer high clinical application value. In the context of bacterial resistance, this article aims to provide a comprehensive review of nemonoxacin\u2019s antibacterial activity, immunomodulatory effects, and its application in infectious diseases as well as in patients with hepatic or renal insufficiency, with the goal of offering more drug options for clinical treatment and providing a reference for future clinical research and widespread application.<\/jats:p>","DOI":"10.3389\/fmed.2025.1671640","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T12:19:05Z","timestamp":1757506745000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["The latest research progress on the clinical application of nemonoxacin"],"prefix":"10.3389","volume":"12","author":[{"given":"Hui","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingchun","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fusheng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,10]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1128\/AAC.00683-09","article-title":"Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers","volume":"54","author":"Chung","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1007\/s40265-014-0270-0","article-title":"Nemonoxacin: first global approval","volume":"74","author":"Poole","year":"2014","journal-title":"Drugs"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3390\/pharmaceutics13081289","article-title":"Structural characterization of the millennial antibacterial (Fluoro)quinolones-shaping the fifth generation","volume":"13","author":"Rusu","year":"2021","journal-title":"Pharmaceutics"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"e0171522","DOI":"10.1128\/spectrum.01715-22","article-title":"Activities of eravacycline, tedizolid, norvancomycin, nemonoxacin, ceftaroline, and comparators against 1, 871 Staphylococcus and 1, 068 Enterococcus species isolates from China: updated report of the CHINET study 2019","volume":"10","author":"Ding","year":"2022","journal-title":"Microbiol Spectr"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12941-016-0150-4","article-title":"Chemical structure and pharmacokinetics of novel quinolone agents represented by avarofloxacin, delafloxacin, finafloxacin, zabofloxacin and nemonoxacin","volume":"15","author":"Kocsis","year":"2016","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.jmii.2018.11.006","article-title":"Integrated safety summary of phase II and III studies comparing oral nemonoxacin and levofloxacin in community-acquired pneumonia","volume":"52","author":"Cheng","year":"2019","journal-title":"J Microbiol Immunol Infect"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"658558","DOI":"10.3389\/fphar.2021.658558","article-title":"Pharmacokinetics and pharmacodynamics of nemonoxacin in a neutropenic murine lung infection model against Streptococcus pneumoniae","volume":"12","author":"Li","year":"2021","journal-title":"Front Pharmacol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"765","DOI":"10.2147\/DDDT.S63581","article-title":"Review of nemonoxacin with special focus on clinical development","volume":"8","author":"Qin","year":"2014","journal-title":"Drug Des Devel Ther"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1089\/mdr.2016.0021","article-title":"In vitro resistance development to nemonoxacin in Streptococcus pneumoniae: a unique profile for a novel nonfluorinated quinolone","volume":"22","author":"Roychoudhury","year":"2016","journal-title":"Microb Drug Resist"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1007\/s10753-020-01296-9","article-title":"Nemonoxacin has immunoprotective effects on reducing mortality in lipopolysaccharide-induced mouse Sepsis model","volume":"43","author":"Chen","year":"2020","journal-title":"Inflammation"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1517\/14656566.2015.978288","article-title":"The potential role of nemonoxacin for treatment of common infections","volume":"16","author":"Huang","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1067686","DOI":"10.3389\/fphar.2022.1067686","article-title":"Safety of oral nemonoxacin: a systematic review of clinical trials and postmarketing surveillance","volume":"13","author":"Yuan","year":"2022","journal-title":"Front Pharmacol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1089\/mdr.2019.0048","article-title":"Selected mutations by nemonoxacin and fluoroquinolone exposure among relevant gram-positive bacterial strains in Taiwan","volume":"26","author":"Yang","year":"2020","journal-title":"Microb Drug Resist"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1093\/jac\/dkq341","article-title":"In vivo antibacterial activity of nemonoxacin, a novel non-fluorinated quinolone","volume":"65","author":"Li","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"e0180021","DOI":"10.1128\/AAC.01800-21","article-title":"Nemonoxacin enhances antibacterial activity and anti-resistance mutation ability of vancomycin against methicillin-resistant Staphylococcus aureus in an in vitro dynamic pharmacokinetic\/Pharmacodynamic model","volume":"66","author":"Huang","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1093\/jac\/dkp370","article-title":"In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan","volume":"64","author":"Chen","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"e0243123","DOI":"10.1128\/spectrum.02431-23","article-title":"In vitro pharmacodynamics of nemonoxacin and other antimicrobial agents against Mycoplasma pneumoniae","volume":"11","author":"Wang","year":"2023","journal-title":"Microbiol Spectr"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1418817","DOI":"10.3389\/fmicb.2024.1418817","article-title":"Potential effectiveness of parenteral nemonoxacin in the treatment of clostridioides difficile infections: in vitro, ex vivo, and mouse studies","volume":"15","author":"Lee","year":"2024","journal-title":"Front Microbiol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"3943","DOI":"10.1128\/AAC.00191-12","article-title":"Characterizations of clinical isolates of Clostridium difficile by toxin genotypes and by susceptibility to 12 antimicrobial agents, including fidaxomicin (OPT-80) and rifaximin: a multicenter study in Taiwan","volume":"56","author":"Liao","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.3760\/cma.j.cn112147-20200813-00896","article-title":"In vitro evaluation of the antibacterial activity of nemonoxacin against Mycobacterium tuberculosis, mycobacterium intracellulare and Mycobacterium abscessus","volume":"43","author":"Jiang","year":"2020","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1007\/s10096-010-1009-9","article-title":"In vitro activity of nemonoxacin, tigecycline, and other antimicrobial agents against Helicobacter pylori isolates in Taiwan, 1998-2007","volume":"29","author":"Yang","year":"2010","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1128\/AAC.01808-10","article-title":"Multicenter study in Taiwan of the in vitro activities of nemonoxacin, tigecycline, doripenem, and other antimicrobial agents against clinical isolates of various Nocardia species","volume":"55","author":"Lai","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1093\/jac\/dkp144","article-title":"Comparative in vitro activities of nemonoxacin, doripenem, tigecycline and 16 other antimicrobials against Nocardia brasiliensis, Nocardia asteroides and unusual Nocardia species","volume":"64","author":"Lai","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s10096-013-1949-y","article-title":"Trends in the susceptibility of methicillin-resistant Staphylococcus aureus to nine antimicrobial agents, including ceftobiprole, nemonoxacin, and tyrothricin: results from the Tigecycline in vitro surveillance in Taiwan (TIST) study, 2006-2010","volume":"33","author":"Chen","year":"2014","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12941-024-00772-6","article-title":"Taiwan Staphylococcus aureus: comparative in vitro antibacterial activity of nemonoxacin and other fluoroquinolones in correlation with resistant mechanisms in contemporary methicillin-resistant Staphylococcus aureus blood isolates in Taiwan","volume":"24","author":"Chen","year":"2025","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"20","DOI":"10.16718\/j.1009-7708.2020.04.001","article-title":"Investigation into the specific immunomodulatory effects of nemonoxacin onmacrophages","author":"Zhang","year":"2020","journal-title":"Chin J Infect Chemother"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/S0140-6736(21)00630-9","article-title":"Restrepo MI. Restrepo: community-acquired pneumonia","volume":"398","author":"Aliberti","year":"2021","journal-title":"Lancet"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"107235","DOI":"10.1016\/j.ijantimicag.2024.107235","article-title":"A multicentre, randomised, double-blind, double-dummy, parallel-controlled, phase 3 clinical trial assessing the efficacy and safety of intravenous nemonoxacin malate vs. levofloxacin for community-acquired pneumonia in adult patients","volume":"64","author":"Li","year":"2024","journal-title":"Int J Antimicrob Agents"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"e37650","DOI":"10.7759\/cureus.37650","article-title":"Safety and efficacy of nemonoxacin vs levofloxacin in patients with community-acquired pneumonia: a systematic review and meta-analysis of randomized control trials","volume":"15","author":"Khan","year":"2023","journal-title":"Cureus"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"912962","DOI":"10.3389\/fphar.2023.912962","article-title":"Integrative population pharmacokinetic\/pharmacodynamic analysis of nemonoxacin capsule in Chinese patients with community-acquired pneumonia","volume":"14","author":"Chen","year":"2023","journal-title":"Front Pharmacol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.2147\/IDR.S248092","article-title":"Efficacy and safety of nemonoxacin in outpatients with community-acquired pneumonia","volume":"13","author":"Zhao","year":"2020","journal-title":"Infect Drug Resist"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3390\/ijerph19084816","article-title":"Economic evaluation of nemonoxacin, moxifloxacin and levofloxacin in the treatment of early community-acquired pneumonia with possible pulmonary tuberculosis","volume":"19","author":"Zhao","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ijid.2013.09.013","article-title":"Community-acquired pneumonia and tuberculosis: differential diagnosis and the use of fluoroquinolones","volume":"18","author":"Grossman","year":"2014","journal-title":"Int J Infect Dis"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"4065","DOI":"10.1007\/s11033-020-05413-7","article-title":"Advances in diagnosis of tuberculosis: an update into molecular diagnosis of Mycobacterium tuberculosis","volume":"47","author":"Acharya","year":"2020","journal-title":"Mol Biol Rep"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/s41579-018-0013-4","article-title":"Metabolic principles of persistence and pathogenicity in Mycobacterium tuberculosis","volume":"16","author":"Ehrt","year":"2018","journal-title":"Nat Rev Microbiol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1055\/s-0040-1710583","article-title":"The great masquerader: tuberculosis presenting as community-acquired pneumonia","volume":"41","author":"Dheda","year":"2020","journal-title":"Semin Respir Crit Care Med"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.rcc.2004.10.007","article-title":"Tuberculosis: still overlooked as a cause of community-acquired pneumonia--how not to miss it","volume":"11","author":"Kunimoto","year":"2005","journal-title":"Respir Care Clin N Am"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.ijantimicag.2011.11.014","article-title":"Does empirical treatment of community-acquired pneumonia with fluoroquinolones delay tuberculosis treatment and result in fluoroquinolone resistance in Mycobacterium tuberculosis? Controversies and solutions","volume":"39","author":"Shen","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"e0309034","DOI":"10.1371\/journal.pone.0309034","article-title":"Patient and provider costs of the new BPaL regimen for drug-resistant tuberculosis treatment in South Africa: a cost-effectiveness analysis","volume":"19","author":"Evans","year":"2024","journal-title":"PLoS One"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"e1004285","DOI":"10.1371\/journal.pmed.1004285","article-title":"Cost-effectiveness analysis of interventions to improve diagnosis and preventive therapy for paediatric tuberculosis in 9 sub-Saharan African countries: a modelling study","volume":"20","author":"Mafirakureva","year":"2023","journal-title":"PLoS Med"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1093\/jac\/dkp174","article-title":"Comparative in vitro activities of the new quinolone nemonoxacin (TG-873870), gemifloxacin and other quinolones against clinical isolates of Mycobacterium tuberculosis","volume":"64","author":"Tan","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1113622","DOI":"10.3389\/fendo.2023.1113622","article-title":"Distribution of microbes and antimicrobial susceptibility in patients with diabetic foot infections in South China","volume":"14","author":"Liu","year":"2023","journal-title":"Front Endocrinol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.3390\/life12071054","article-title":"An overview of diabetic foot ulcers and associated problems with special emphasis on treatments with antimicrobials","volume":"12","author":"Baig","year":"2022","journal-title":"Life"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"397","DOI":"10.4172\/2332-0877.1000397","article-title":"A pilot study of nemonoxacin in patients with diabetic foot infections","volume":"7","author":"Lipsky","year":"2019","journal-title":"J Infect Dis Therapy"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1164\/rccm.201204-0596PP","article-title":"Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary","volume":"187","author":"Vestbo","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1016\/S0140-6736(22)00470-6","article-title":"Chronic obstructive pulmonary disease","volume":"399","author":"Christenson","year":"2022","journal-title":"Lancet"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"ITC17-ITC32","DOI":"10.7326\/AITC202008040","article-title":"Chronic obstructive pulmonary disease","volume":"173","author":"Labaki","year":"2020","journal-title":"Ann Intern Med"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.ccm.2020.06.007","article-title":"Definition, causes, pathogenesis, and consequences of chronic obstructive pulmonary disease exacerbations","volume":"41","author":"Ritchie","year":"2020","journal-title":"Clin Chest Med"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.2147\/COPD.S433183","article-title":"Analyses of factors associated with acute exacerbations of chronic obstructive pulmonary disease: a review","volume":"18","author":"Qian","year":"2023","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.rmr.2022.02.056","article-title":"Physiotherapy during and after acute exacerbation of COPD","volume":"39","author":"Medrinal","year":"2022","journal-title":"Rev Mal Respir"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"170","DOI":"10.3760\/cma.j.cn112147-20210109-00031","article-title":"Guidelines for the diagnosis and management of chronic obstructive pulmonary disease (revised version 2021)","volume":"44","year":"2021","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"16954","DOI":"10.1038\/s41598-023-44188-2","article-title":"Nemonoxacin achieved a better symptomatic improvement and a prolonged interval to next exacerbation than moxifloxacin for outpatients with acute exacerbations of chronic obstructive pulmonary disease","volume":"13","author":"Meng","year":"2023","journal-title":"Sci Rep"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.cvsm.2018.11.005","article-title":"Urinary tract infection","volume":"49","author":"Byron","year":"2019","journal-title":"Vet Clin North Am Small Anim Pract"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"373","DOI":"10.3238\/arztebl.m2024.0068","article-title":"The diagnosis, treatment, and prevention of recurrent urinary tract infection","volume":"121","author":"Schmiemann","year":"2024","journal-title":"Dtsch Arztebl Int"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.idc.2021.08.003","article-title":"Urinary tract infections: 2021 update","volume":"35","author":"Chenoweth","year":"2021","journal-title":"Infect Dis Clin N Am"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1186\/s12879-025-10915-5","article-title":"Clinical utility of oral nemonoxacin 500 mg once daily for the treatment of acute lower urinary tract infections: a prospective open-label, multicenter study","volume":"25","author":"Du","year":"2025","journal-title":"BMC Infect Dis"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.3969\/j.issn.1002-1949.2020.11.004","article-title":"Emergency Physicians Branch of Chinese Medical Doctor Association, Emergency Medicine Branch of Chinese Medical Association, China Emergency Specialized Medical Association, Beijing Emergency Medicine Society, Zhao XD, Lv CZ, et al. Guidelines for the emergency clinical application of quinolone antibacterial drugs","volume":"40","year":"2020","journal-title":"Chin Emerg Med"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"4636","DOI":"10.1111\/bcp.14881","article-title":"Nemonoxacin dosage adjustment in patients with severe renal impairment based on population pharmacokinetic and pharmacodynamic analysis","volume":"87","author":"Li","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.clinthera.2019.01.015","article-title":"Population pharmacokinetics study of nemonoxacin among Chinese patients with moderate hepatic impairment","volume":"41","author":"Kang","year":"2019","journal-title":"Clin Ther"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1586\/14787210.2014.894881","article-title":"Nemonoxacin (TG-873870) for treatment of community-acquired pneumonia","volume":"12","author":"Lai","year":"2014","journal-title":"Expert Rev Anti-Infect Ther"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.ijantimicag.2010.12.003","article-title":"In vitro susceptibilities of clinical isolates of ertapenem-non-susceptible Enterobacteriaceae to nemonoxacin, tigecycline, fosfomycin and other antimicrobial agents","volume":"37","author":"Hsu","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.3389\/fmicb.2019.01890","article-title":"In vitro activities of nemonoxacin and other antimicrobial agents against human Mycoplasma and Ureaplasmas isolates and their defined resistance mechanisms","volume":"10","author":"Wang","year":"2019","journal-title":"Front Microbiol"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"947","DOI":"10.3760\/cma.j.cn112147-20210507-00311","article-title":"In vitro evaluation of the antibacterial activity of nemonoxacin against Mycobacterium abscessus","volume":"44","author":"Li","year":"2021","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.clinthera.2018.04.014","article-title":"Effects of nemonoxacin on thorough ECG QT\/QTc interval: a randomized, placebo-and positive-controlled crossover study in healthy Chinese adults","volume":"40","author":"Zhao","year":"2018","journal-title":"Clin Ther"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1016\/S2213-2600(20)30071-0","article-title":"Therapeutic and triage strategies for 2019 novel coronavirus disease in fever clinics","volume":"8","author":"Zhang","year":"2020","journal-title":"Lancet Respir Med"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"e001002","DOI":"10.1136\/bmjophth-2022-001002","article-title":"Potential new fluoroquinolone treatments for suspected bacterial keratitis","volume":"7","author":"Herbert","year":"2022","journal-title":"BMJ Open Ophthalmol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1671640\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T12:19:11Z","timestamp":1757506751000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1671640\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,10]]},"references-count":66,"alternative-id":["10.3389\/fmed.2025.1671640"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1671640","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,10]]},"article-number":"1671640"}}